TY - JOUR
T1 - Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
AU - Musto, Pellegrino
AU - Montefusco, Vittorio
PY - 2016/6/16
Y1 - 2016/6/16
N2 - Maintenance therapy after autologous stem cell transplantation, as well as continuous regimens for older, transplant ineligible patients, are emerging as an effective strategy to control the minimal residual disease that persists after response to initial treatments and is the main cause of relapse in patients affected by multiple myeloma (MM). However, though such approaches have consistently demonstrated in clinical trials to be able to delay disease recurrence, thus improving progression-free survival and, at least in some studies, overall survival, the use of these long term therapies (LTTs) in the daily clinical practice is not uniformly applied and some questions remains unanswered. This article aims to provide a synthetic discussion of the most consistent data on novel agent-based LTTs in newly diagnosed MM, to recognize the best candidate for these treatments and to describe a landscape of their possible future application.
AB - Maintenance therapy after autologous stem cell transplantation, as well as continuous regimens for older, transplant ineligible patients, are emerging as an effective strategy to control the minimal residual disease that persists after response to initial treatments and is the main cause of relapse in patients affected by multiple myeloma (MM). However, though such approaches have consistently demonstrated in clinical trials to be able to delay disease recurrence, thus improving progression-free survival and, at least in some studies, overall survival, the use of these long term therapies (LTTs) in the daily clinical practice is not uniformly applied and some questions remains unanswered. This article aims to provide a synthetic discussion of the most consistent data on novel agent-based LTTs in newly diagnosed MM, to recognize the best candidate for these treatments and to describe a landscape of their possible future application.
KW - bortezomib
KW - carfilzomib
KW - continuous therapy
KW - daratumumab
KW - elotuzumab
KW - ixazomib
KW - lenalidomide
KW - maintenance therapy
KW - minimal residual disease
KW - Multiple myeloma
KW - thalidomide
UR - http://www.scopus.com/inward/record.url?scp=84976873282&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976873282&partnerID=8YFLogxK
U2 - 10.1080/17474086.2016.1196127
DO - 10.1080/17474086.2016.1196127
M3 - Article
AN - SCOPUS:84976873282
SP - 1
EP - 9
JO - Expert Review of Hematology
JF - Expert Review of Hematology
SN - 1747-4086
ER -